COMP <GO>
HALO vs NBIX // RETURN ON INVESTED CAPITAL (ROIC)
Halozyme Therapeutics Inc. (NASDAQ) VS. Neurocrine Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: HALO 6
— NBIX 7
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: HALO
LAST: $131.18 (+0.88%) • MKT CAP: $14.89B
roic
18.00%
LAST: $146.38 (+0.58%) • MKT CAP: $14.88B
roic
15.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HALO VS. NBIX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HALO | NBIX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 83.60% | 96.00% | -12.40 | NBIX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 18.00% | 15.70% | +2.30 | HALO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 35.6x | 22.8x | +12.80 | NBIX | /valuation <GO> |
| Free Cash Flow Yield | 4.33% | 5.03% | -0.70 | NBIX | /fcf-yield <GO> |
| Operating Margin | 33.60% | 21.60% | +12.00 | HALO | /operating-margins <GO> |
| Net Profit Margin | 22.70% | 16.70% | +6.00 | HALO | /net-margins <GO> |
| Revenue Growth (YoY) | 37.60% | 21.40% | +16.20 | HALO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.11 | 8.13 | -3.02 | NBIX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | NBIX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 79.0 | 56.1 | +22.90 | HALO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 1.13 | -0.25 | NBIX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 39.5x | 26.1x | +13.40 | NBIX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $14.89B | $14.88B | $9.3M | HALO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HALO REV | NBIX REV | HALO GROSS % | NBIX GROSS % | HALO FCF | NBIX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.40B | $2.86B | 83.6% | 98.2% | $644.6M | $748.7M |
| FY 2024 | $1.02B | $2.36B | 84.3% | 98.6% | $468.4M | $557.2M |
| FY 2023 | $829.3M | $1.89B | — | — | $351.3M | $305.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HALO // BETA 0.88
NBIX // BETA 1.13